"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study
Breathlessness or dyspnea in terminal cancer patients with lung cancer is common and opioids
such as morphine is the mainstay of symptomatic treatment. Subcutaneous administration of
morphine provides fast symptomatic relief, but it has been the impression in our institution
that "red morphine drops" applied orally may have equal or better efficacy and faster onset
time.
Comparison: Patients with lung cancer or lung metastases with moderate to severe dyspnea at
rest are treated with either orally applied "red morphine drops" or an equivalent amount of
morphine applied subcutaneously.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Dyspnea on a VAS scale
1 hour
No
Torben Krantz, Physician
Principal Investigator
Sankt Lukas Hospice
Denmark: Danish Medicines Agency
2005-060-version1a
NCT00338481
April 2006
February 2011
Name | Location |
---|